Caribou Biosciences Future Growth

Future criteria checks 2/6

Caribou Biosciences's earnings are forecast to decline at 7.2% per annum while its annual revenue is expected to grow at 54.3% per year. EPS is expected to decline by 0.7% per annum. Return on equity is forecast to be -65.4% in 3 years.

Key information

-7.2%

Earnings growth rate

-0.7%

EPS growth rate

Biotechs earnings growth	24.8%
Revenue growth rate	54.3%
Future return on equity	-65.4%
Analyst coverage	Good
Last updated	10 May 2024

Recent future growth updates

Recent updates

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

Earnings and Revenue Growth Forecasts

NasdaqGS:CRBU - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	75	-213	-208	-178	5
12/31/2025	13	-218	-190	-165	8
12/31/2024	12	-167	-152	-142	8
3/31/2024	33	-115	-115	-103	N/A
12/31/2023	34	-102	-105	-93	N/A
9/30/2023	35	-95	-108	-97	N/A
6/30/2023	14	-111	-99	-91	N/A
3/31/2023	15	-108	-106	-97	N/A
12/31/2022	14	-99	-98	-91	N/A
9/30/2022	13	-91	-93	-87	N/A
6/30/2022	13	-85	-86	-80	N/A
3/31/2022	11	-73	-78	-75	N/A
12/31/2021	10	-67	-36	-33	N/A
9/30/2021	8	-63	-22	-19	N/A
6/30/2021	5	-50	-14	-13	N/A
3/31/2021	12	-38	-4	-4	N/A
12/31/2020	12	-34	-35	-33	N/A
12/31/2019	6	-23	-33	-32	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRBU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRBU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRBU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRBU's revenue (54.3% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: CRBU's revenue (54.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CRBU is forecast to be unprofitable in 3 years.

Caribou Biosciences Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 8.0% to US$20.25

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Consensus revenue estimates decrease by 19%, EPS upgraded

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Recent updates

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Chief Scientific Officer exercised options and sold US$369k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences, Inc. Announces Board Changes

Caribou Biosciences, Inc., Annual General Meeting, Sep 20, 2022

Caribou Biosciences, Inc.(NasdaqGS:CRBU) dropped from Russell 2000 Growth Index

Caribou Biosciences, Inc. Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

Chief Scientific Officer exercised options to buy US$643k worth of stock.

Crispred CAR-T Cells In The Clinic

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

Caribou Biosciences, Inc. Appoints David Johnson to its Board of Directors

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences, Inc. Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)

Caribou Biosciences: Selling Close To Cash Balance

Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress

Caribou Biosciences, Inc. Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at American Association for Cancer Research Annual Meeting

Consensus estimates of losses per share improve by 13%

Caribou Biosciences, Inc. to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

Chief Financial Officer exercised options to buy US$309k worth of stock.

Third quarter 2021 earnings released: US$0.46 loss per share

Less than half of directors are independent

Less than half of directors are independent

We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold